Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness
- PMID: 30107412
- PMCID: PMC6284547
- DOI: 10.1093/infdis/jiy477
Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness
Abstract
Background: Transplacental respiratory syncytial virus (RSV) antibody transfer has been characterized, but little is known about the protective effect of breast milk RSV-specific antibodies. Serum antibodies against the prefusion RSV fusion protein (pre-F) exhibit high neutralizing activity. We investigate protection of breast milk pre-F antibodies against RSV acute respiratory infection (ARI).
Methods: Breast milk at 1, 3, and 6 months postpartum and midnasal swabs during infant illness episodes were collected in mother-infant pairs in Nepal. One hundred seventy-four infants with and without RSV ARI were matched 1:1 by risk factors for RSV ARI. Pre-F immunoglobulin A (IgA) and immunoglobulin G (IgG) antibody levels were measured in breast milk.
Results: The median breast milk pre-F IgG antibody concentration before illness was lower in mothers of infants with RSV ARI (1.4 [interquartile range {IQR}, 1.1-1.6] log10 ng/mL) than without RSV ARI (1.5 [IQR, 1.3-1.8] log10 ng/mL) (P = .001). There was no difference in median maternal pre-F IgA antibody concentrations in cases vs controls (1.7 [IQR, 0.0-2.2] log10 ng/mL vs 1.7 [IQR, 1.2-2.2] log10 ng/mL, respectively; P = .58).
Conclusions: Low breast milk pre-F IgG antibodies before RSV ARI support a potential role for pre-F IgG as a correlate of protection against RSV ARI. Induction of breast milk pre-F IgG may be a mechanism of protection for maternal RSV vaccines.
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6284547/bin/jiy47701.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6284547/bin/jiy47702.gif)
Similar articles
-
Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.Vaccine. 2019 Sep 24;37(41):6112-6124. doi: 10.1016/j.vaccine.2019.07.089. Epub 2019 Aug 12. Vaccine. 2019. PMID: 31416644
-
Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.J Infect Dis. 2017 Dec 12;216(11):1398-1406. doi: 10.1093/infdis/jix489. J Infect Dis. 2017. PMID: 29029312 Free PMC article.
-
A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.Vaccine. 2017 Jun 27;35(30):3749-3759. doi: 10.1016/j.vaccine.2017.05.045. Epub 2017 Jun 1. Vaccine. 2017. PMID: 28579233 Clinical Trial.
-
Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1817-1827. doi: 10.1007/s10096-018-3289-4. Epub 2018 Jun 6. Eur J Clin Microbiol Infect Dis. 2018. PMID: 29876771 Review.
-
Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody.Pediatr Infect Dis J. 1994 May;13(5):449-53. doi: 10.1097/00006454-199405000-00037. Pediatr Infect Dis J. 1994. PMID: 8072835 Review.
Cited by
-
Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure.Front Immunol. 2024 Apr 30;15:1377374. doi: 10.3389/fimmu.2024.1377374. eCollection 2024. Front Immunol. 2024. PMID: 38745662 Free PMC article.
-
COVID-19 booster enhances IgG mediated viral neutralization by human milk in vitro.Front Nutr. 2024 Feb 9;11:1289413. doi: 10.3389/fnut.2024.1289413. eCollection 2024. Front Nutr. 2024. PMID: 38406184 Free PMC article.
-
Efficacy and safety of respiratory syncytial virus vaccination during pregnancy to prevent lower respiratory tract illness in newborns and infants: a systematic review and meta-analysis of randomized controlled trials.Front Pediatr. 2024 Jan 31;11:1260740. doi: 10.3389/fped.2023.1260740. eCollection 2023. Front Pediatr. 2024. PMID: 38357264 Free PMC article. Review.
-
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.J Infect Dis. 2023 Aug 11;228(3):299-310. doi: 10.1093/infdis/jiad024. J Infect Dis. 2023. PMID: 36722147 Free PMC article. Clinical Trial.
-
Safety and Efficacy of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines During Lactation.Obstet Gynecol. 2023 Mar 1;141(3):483-491. doi: 10.1097/AOG.0000000000005093. Epub 2023 Jan 18. Obstet Gynecol. 2023. PMID: 36649326 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous